Skip to content

Hero image: A reproductive genetics team explaining mitochondrial inheritance to a couple using a clear laboratory model

All insights

Specialist & Emerging Care

Mitochondrial Donation: Preventing Inherited Disease Under Strict National Rules

10 min readEvidence synthesis
Read the evidence

The question in focus

An evidence-based explanation of mitochondrial donation, who may be eligible, early outcomes, residual risk, lifelong follow-up and international regulation.

Evidence at a glance

8 births

reported after regulated UK mitochondrial donation by July 2025

Early UK reports described eight babies after treatment. The sample is very small, and long-term follow-up remains essential.

HFEA Comments on Eight Babies Born After Mitochondrial Donation

Mitochondrial disease follows a distinct inheritance pathway

Mitochondria produce cellular energy and contain a small amount of DNA separate from nuclear DNA. Mitochondrial DNA is inherited through the egg. Harmful variants can affect organs with high energy demands and cause severe neurological, muscular, cardiac or multisystem disease. The proportion of variant mitochondrial DNA can differ among eggs, tissues and family members, making individual risk difficult to predict.

For some families, preimplantation genetic testing can identify embryos with lower variant levels. For others with very high or unpredictable transmission risk, mitochondrial donation may be considered. It combines the intended parents' nuclear DNA with healthy mitochondria from a donated egg. The technique aims to reduce transmission of mitochondrial DNA disease, not to treat infertility generally or alter chosen traits [1].

  • Confirm the exact mitochondrial DNA diagnosis and estimated transmission risk.
  • Compare natural conception, prenatal diagnosis, PGT, donor oocyte and mitochondrial donation.
  • Use specialist reproductive genetics counselling before treatment.

The UK pathway is case-by-case, not routine IVF

The UK legalised regulated mitochondrial donation in 2015. Treatment can occur only in an HFEA-licensed clinic, and each patient application is individually approved when there is a very high risk of transmitting serious mitochondrial disease [1]. This national framework includes technical licensing, case review, consent and follow-up arrangements.

HFEA reported that 35 patients had received approval as of 1 July 2025 and confirmed reports of eight births [2]. These numbers demonstrate feasibility, not population-level effectiveness. Access remains extremely limited, and eligibility is not established by having a family history alone. Genetic confirmation, reproductive assessment and regulatory approval are required.

  • Verify the clinic's licence and the national approval process.
  • Do not infer eligibility from online descriptions.
  • Explain donor screening, consent and information rights.

Early outcomes are encouraging and still early

A 2025 New England Journal of Medicine report described mitochondrial donation in a reproductive pathway for 22 patients and eight births, with one ongoing pregnancy at the time of reporting [3]. The children were reported healthy at the available follow-up, and disease-causing mitochondrial DNA was undetectable or below levels expected to cause disease in most reported samples. The cohort remains too small and young for definitive long-term conclusions.

A small amount of maternal mitochondria can be carried over during nuclear transfer, and its proportion may change during development. This is called carryover and, when levels rise, reversion. It is one reason why mitochondrial donation reduces risk rather than guaranteeing zero transmission. Follow-up needs to include development and appropriate molecular assessment without turning children into research subjects beyond valid consent and welfare safeguards.

  • Report carryover and follow-up methods, not only birth count.
  • Explain residual risk in plain language.
  • Plan paediatric follow-up before embryo transfer.

Mitochondrial donation changes genetic material that can be inherited by later generations. Regulation therefore differs from ordinary donor-oocyte IVF. In the United States, FDA states that Congress has prohibited it from accepting applications for clinical research using mitochondrial replacement techniques, so human clinical research cannot legally proceed under the current framework [4].

The UK and Australia have created specific regulated routes, while many countries prohibit or have no defined pathway. Cross-border treatment can expose families to variable laboratory standards, follow-up and legal protections. A platform operating internationally must show country-specific status and referral, not a single global availability label. Marketing language such as guaranteed disease-free baby is scientifically and ethically unacceptable.

  • Check the law where laboratory work and embryo transfer occur.
  • Confirm who regulates long-term follow-up and adverse-event reporting.
  • Avoid cross-border referral to unlicensed or opaque providers.

Governance must travel across generations

Consent needs to address embryo creation, donor information, storage, prenatal testing, childhood follow-up, future contact and the possibility that knowledge changes. UK regulation requires structured follow-up and oversight, while the National Academies identified long-term, intergenerational governance as central to responsible introduction [1][5]. Children should receive age-appropriate information as they mature. Researchers also need plans for privacy because mitochondrial variants and family relationships can identify multiple relatives.

A registry can support safety by recording technique, embryology, pregnancy, birth, molecular findings and long-term outcomes. It should publish aggregate results and adverse events while protecting families. The right metric is not treatment volume. It is whether carefully selected families receive accurate counselling, regulated care and sustained follow-up that can detect both benefit and unexpected harm.

  • Separate consent for clinical follow-up from optional research.
  • Maintain a route for updating families when evidence changes.
  • Use independent oversight for long-term registry governance.

What the evidence cannot yet answer

  • Published human outcomes involve very small numbers and short childhood follow-up.
  • Residual maternal mitochondrial DNA can persist or change in proportion, so risk is reduced rather than eliminated.
  • Availability and legality are country-specific and may change; findings from one regulated system cannot authorise use elsewhere.

Questions worth taking into care

  1. What pathogenic mitochondrial DNA variant is present and how certain is the transmission risk?
  2. Could PGT, donor oocytes or prenatal diagnosis meet the family's goals?
  3. Is the treatment and clinic legally authorised for this use?
  4. How does the laboratory measure and report mitochondrial carryover?
  5. What lifelong follow-up and data governance are offered to the child and family?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
    Mitochondrial Donation Treatment

    Human Fertilisation and Embryology Authority · 2025

  2. [2]
    HFEA Comments on Eight Babies Born After Mitochondrial Donation Treatment

    Human Fertilisation and Embryology Authority · 2025

  3. [3]
  4. [4]
  5. [5]
    Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations

    National Academies of Sciences, Engineering, and Medicine · 2016

Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.